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 Parmodulins are a new class of PAR1 inhibitors that target the cytosolic 
face of PAR1 to block signaling through Gαq, but not Gα12/13. 
 Unlike vorapaxar, which causes endothelial injury, parmodulins 
selectively block proinflammatory, but not cytoprotective, signaling. 
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Abstract: Protease-activated receptor-1 (PAR1) couples the coagulation 
cascade to platelet activation during myocardial infarction and to endothelial 
inflammation during sepsis. This receptor demonstrates marked signaling 
bias. Its activation by thrombin stimulates prothrombotic and 
proinflammatory signaling, whereas its activation by activated protein C (APC) 
stimulates cytoprotective and antiinflammatory signaling. A challenge in 
developing PAR1-targeted therapies is to inhibit detrimental signaling while 
sparing beneficial pathways. We now characterize a novel class of structurally 
unrelated small-molecule PAR1 antagonists, termed parmodulins, and 
compare the activity of these compounds to previously characterized 
compounds that act at the PAR1 ligand–binding site. We find that parmodulins 
target the cytoplasmic face of PAR1 without modifying the ligand-binding site, 
blocking signaling through Gαq but not Gα13 in vitro and thrombus formation 
in vivo. In endothelium, parmodulins inhibit prothrombotic and 
proinflammatory signaling without blocking APC-mediated pathways or 
inducing endothelial injury. In contrast, orthosteric PAR1 antagonists such as 
vorapaxar inhibit all signaling downstream of PAR1. Furthermore, exposure of 
endothelial cells to nanomolar concentrations of vorapaxar induces endothelial 
cell barrier dysfunction and apoptosis. These studies demonstrate how 
functionally selective antagonism can be achieved by targeting the 
cytoplasmic face of a G-protein–coupled receptor to selectively block 
pathologic signaling while preserving cytoprotective pathways. 
Introduction 
Protease-activated receptor 1 (PAR1) is a widely expressed G-
protein–coupled receptor (GPCR) that detects proteases in the 
extracellular environment with high sensitivity. It is activated by an 
intramolecular signaling mechanism whereby cleavage of the N-
terminus of the receptor by a protease exposes a tethered ligand that 
interacts with a shallow, extended binding site on the extracellular face 
of the receptor.1 The effective concentration of the tethered ligand is 
high, owing to entropy considerations and has been estimated to be 
∼400 μM, making the ligand difficult to block using soluble 
antagonists.1 The molecular pharmacology of PAR1 is further 
complicated by the fact that PAR1 is a functionally-biased receptor that 
activates different signaling cascades depending on the proteases by 
which it is cleaved and the cell type on which it resides. The signaling 
bias of PAR1 is particularly prominent in endothelial cells, in which 
activation of PAR1 by thrombin or metalloproteases results in loss of 
barrier function and apoptosis,2-4 whereas activation of PAR1 by 
activated protein C (APC) is protective against loss of barrier function 
and apoptosis induced by chemokines and toxins.5-11 
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PAR1 has been the focus of several drug development 
programs, owing to the importance of platelet PAR1 in myocardial 
infarction and stroke. Two fundamental problems in developing small-
molecule inhibitors of PAR1 have been (1) identifying compounds 
capable of competing with the tethered ligand at its binding site and 
(2) blocking the detrimental effects of PAR1 signaling while preserving 
its cytoprotective signaling. Several small-molecule inhibitors of PAR1 
that effectively compete with the ligand binding site have been 
developed.12-16 The most well-characterized of these orthosteric 
inhibitors is vorapaxar, which recently received Food and Drug 
Administration approval for the prevention of thrombotic 
cardiovascular events in high-risk patients. Vorapaxar has been 
evaluated in 2 large, randomized phase 3 clinical studies in the 
settings of acute coronary syndromes (TRACER)17 and in secondary 
prevention of atherothrombotic events (TRA-2P).18 Its use was 
associated with decreased cardiovascular death or ischemic events in 
the secondary prevention trial.18 However, vorapaxar recipients had a 
significantly increased incidence of major bleeding, including 
intracranial hemorrhage, in both studies. Meta-analyses of clinical 
trials evaluating vorapaxar and a second orthosteric PAR1 antagonist, 
atopaxar, confirm an association of these inhibitors with bleeding 
risk.19,20 
Like vorapaxar and atopaxar, the vast majority of small-
molecule GPCR antagonists in clinical use target the ligand-binding 
pocket. However, selective control of downstream G-protein–coupled 
signaling pathways may be achieved by targeting alternative binding 
sites.21 This approach is particularly relevant for GPCRs such as PAR1, 
which mediates signaling through pathologic and protective pathways 
that are distinct and separable. We now describe a new class of PAR1 
antagonists termed parmodulins. These compounds act at the cytosolic 
face of PAR1 and selectively inhibit some, but not all, Gα-mediated 
signaling cascades in platelets and endothelial cells. We find that 
orthosteric antagonists such as vorapaxar inhibit cytoprotective 
signaling and elicit endothelial injury, even at nanomolar 
concentrations achieved in plasma with dosing regimens described in 
clinical studies. In contrast, parmodulins inhibit proinflammatory 
signaling without blocking APC-mediated protective effects or eliciting 
apoptosis. These studies demonstrate that functionally selective 
compounds that target the cytosolic surface represent an important 
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alternative to orthosteric antagonists for GPCRs with functional 
signaling bias. 
Methods 
Reagents and compounds 
Parmodulins were either synthesized at the Broad Institute or 
purchased from ChemBridge. Vorapaxar and atopaxar were obtained 
from Axon Medchem BV. SCH79797 and probenecid were obtained 
from Tocris. The PAR1 agonist SFLLRN, the PAR4 agonist AYPGKF, and 
BMS-200261 were obtained from Sigma-Aldrich. Fura-2 was obtained 
from Life Technologies. Tissue-culture reagents were obtained from 
Lonza. COS-7 cells, human umbilical vein endothelial cells (HUVECs), 
and human microvascular endothelial cells (HMVECs) were obtained 
from ATCC. High-affinity thrombin-receptor–activating peptide 
(haTRAP, Ala-Phe[p-F]-Arg-ChA-HArg-[(3)H]Tyr-NH[2])14 was 
synthesized by the Tufts Analytical Core Facility. Human APC was 
obtained from Haematological Technologies. Radiolabeled [3H]haTRAP 
was obtained from PerkinElmer, Inc. Glass microfiber filters were 
purchased from Whatman. Rat anti-mouse GPIbβ antibody conjugated 
to DyLight 649 was obtained from Emfret. 
PAR receptor constructs 
AP-PAR1 and AP-PAR4 constructs used for transfection were a 
generous gift from Dr Shaun R. Coughlin, University of California–San 
Francisco. A construct encoding for a PAR1 ΔH8 mutant, in which 
amino acid residues S376-L386 are replaced with an A-A-A linker, was a 
generous gift of Dr. Athan Kuliopulos, Sackler School of Graduate 
Biomedical Sciences, Tufts University. A detailed description of 
chimeric construct generation and expression in COS-7 cells is 
provided in the supplemental Methods, available on the Blood Web 
site. 
Ca2+ flux measurements 
Ca2+ flux was evaluated using fluorometry in COS-7 cells 
expressing human PAR1, PAR4, PAR1:PAR4 chimeras, the ΔH8 PAR1 
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mutant, or washed platelets. Detailed methods are provided in the 
supplemental Methods. 
Platelet aggregation 
Aggregation of platelet-rich plasma or washed platelets was 
initiated by the indicated concentrations of agonists and measured 
using a ChronoLog 680 Aggregation System as described previously.22 
Experiments using epinephrine were performed in the presence of 50 
U/mL hirudin to prevent thrombin formation. Parmodulins were used 
at the lowest concentration, resulting in >90% inhibition of the 
aggregation of washed platelets in response to 5 μM SFLLRN. Studies 
assessing reversibility of inhibition are described in the supplemental 
Methods. 
RhoA-GTP assay 
Washed platelets (2 × 108/mL in HEPES-Tyrode buffer) or 
HUVECs plated in 6-well platelets were incubated with the indicated 
parmodulins or orthosteric inhibitors and then activated with 10 μM 
SFLLRN for 1 minutes before lysis. Five μL lysate was kept for analysis 
of total protein expression and the remaining lysate used to precipitate 
GTP-bound protein using agarose beads conjugated to GST-Rhotekin-
RBD for RhoA (Cytoskeleton). Total and precipitated GTPase protein 
was measured by immunoblot analysis and visualized using enhanced 
chemoluminescence. Gels representative of 3 to 5 trials for each 
condition are presented. 
Equilibrium-binding studies 
Platelet membranes were prepared from outdated human donor 
platelets supplied by the blood bank at Beth Israel Deaconess Medical 
Center and BloodSource as previously described.22 Binding studies 
were performed in triplicate in 1.5 mL Eppendorf tubes at a final assay 
volume of 200 μL. Bovine serum albumin (0.1%) was included in the 
incubation buffer and filter plates were presoaked in 0.1% 
polyethyleneimine to reduce binding of [3H]haTRAP to tubes and 
pipette tips. [3H]haTRAP (25 nM) was mixed with the indicated 
concentration of compounds or vehicle in binding buffer (50 mM Tris-
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HCl, pH 7.5, 10 mM MgCl2, 1 mM ethylene glycol tetraacetic acid 
(EGTA), 0.1% bovine serum albumin). The reaction was initiated with 
the addition of membranes (0.4 mg/mL) to the reaction mixture. The 
tubes were capped and mixed gently in a water-bath shaker for 1 hour 
at room temperature. The reaction was stopped via vacuum filtration 
using Whatman GF/B filters presoaked for at least 1 hour in 0.1% 
polyethyleneimine. Filters were rapidly washed 4 times with 300 μL of 
ice-cold 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA. The filters 
were then added to individual scintillation vials. Five mL of Ultima Gold 
Scintillation cocktail was added to each vial, and the plates were 
counted in a scintillation counter. Binding of [3H]haTRAP to platelet 
membranes was analyzed using nonlinear regression to obtain 
apparent Kd and βmax. 
Apoptosis assay 
The detection of apoptotic HUVECs was analyzed using a 
modified version of the Vybrant apoptosis kit #4 (Life Technologies). 
HUVECs were seeded onto glass coverslips in 24-well plates and grown 
until they were confluent. Cells were treated with the indicated 
concentrations of antagonists followed by the addition of Yo-Pro-1 as 
directed by the manufacturer. After Yo-Pro-1 labeling, cells were fixed 
with 4% paraformaldehyde in phosphate-buffered saline. Cells were 
washed in phosphate-buffered saline and subsequently stained with 
300 nM 4,6 diamidino-2-phenylindole (DAPI). Coverslips were 
mounted onto glass slides with Aqua Poly/Mount (Polysciences, Inc.) 
and allowed to cure overnight. Micrographs were captured using a 20X 
Olympus Plan Achromat Objective, 0.4 NA, 1.2 mm WD fitted onto an 
Olympus Bx62 microscope with attached Hamamatsu Orca AG camera. 
The microscope, filters, and camera were controlled by Slidebook. 
Images were exported into ImageJ for analysis of cells stained with 
Yo-Pro-1 divided by the total cell count. Data were expressed as % 
apoptotic cells. 
Endothelial exocytosis assays 
HUVECs or human aortic endothelial cells were seeded in 6-well 
plates and grown until they were confluent. Cells were washed twice 
and incubated in EBM2 serum-free medium for 2 hours at 37°C. After 
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preincubation of HUVECs with vorapaxar (0.3 µM), parmodulin 2 (10 
µM) or vehicle (dimethyl sulfoxide) for 30 minutes, cells were exposed 
to buffer or SFLLRN (10 µM) for 1 hour at 37°C. The supernatants 
from endothelial cells were collected and centrifuged for 3 minutes at 
1500g to remove cell debris. von Willebrand factor (VWF) antigen 
levels were quantified using a sandwich enzyme-linked immunosorbent 
assay (ELISA) as described previously.23 
Transendothelial electric resistance 
Transendothelial electric resistance (TER) was measured using 
an electric cell-substrate impedance sensing system (Applied 
BioPhysics Inc.). Values were pooled at discrete time points and were 
either plotted vs time or reported as bar graphs at the time point of 
maximal response to a given stimulus, as described elsewhere in 
detail.24 Each condition’s end-point resistance was divided by its 
starting resistance to give the normalized TER. Confluence was 
determined by the monolayer achieving manufacturer-recommended 
electric criteria (resistance >1800 ohms and capacitance <10 nF). 
Transfection of siRNA 
HUVECs were grown on glass coverslips until they were 70% 
confluent. Transfections were performed with Lipofectamine RNAiMAX 
(Life Technologies) according to the manufacturer’s instructions. 
Validated siRNA for PAR1 was purchased from Life Technologies (Cat. 
#4390824). Confirmation of knockdown was completed using TaqMan 
gene expression assay (ID #Hs00169258_m1) according to the 
manufacturer’s instructions. Isolation of total RNA was completed 
using the PureLink RNA mini kit (Life Technologies) and cDNA 
synthesis was completed using the Superscript Vilo cDNA synthesis kit 
(Life Technologies) according to the manufacturer’s instructions. 
Laser-induced injury 
The effect of parmodulin 2 on thrombus formation was 
evaluated by monitoring platelet accumulation after laser-induced 
injury of cremaster arterioles as previously described19 and detailed 
the supplemental Methods. 
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Tail-tip amputation assay 
Hemostasis was evaluated using a tail-tip amputation assay as 
detailed in the supplemental Methods. 
Results 
Identification of 2 classes of PAR1 antagonists 
In performing high-throughput screening for inhibitors of 
platelet activation induced by the PAR1-activating peptide, SFLLRN, we 
previously identified 4 structurally unrelated inhibitors of SFLLRN-
induced dense granule release (Figure 1A).22,25-27 We compared the 
activity of these compounds with that of orthosteric antagonists of 
PAR1. Orthosteric antagonists included vorapaxar, atopaxar, 
SCH79797, and BMS-200261 (Figure 1B). To determine which PAR1 
inhibitors targeted extracellular binding sites and which targeted the 
cytosolic face of PAR1, we evaluated their activity in COS-7 cells 
expressing either wild-type human PAR1 or a PAR1/PAR4CT chimera 
consisting of amino acids 1 to 365 of PAR1 and 334 to 385 of the C-
terminus of PAR4. The PAR4 cytoplasmic tail was used because none of 
these compounds inhibits platelet activation mediated through 
PAR4.22,25-27 Expression levels of receptors were quantified using an 
alkaline phosphatase assay (supplemental Figure 1). All compounds 
inhibited [Ca2+]i flux stimulated by the PAR1-specific agonist SFLLRN 
when tested in COS-7 cells overexpressing PAR1 (Figure 1C). All 
orthosteric antagonists also inhibited activation of the PAR1/PAR4CT 
chimera (Figure 1D). In contrast, none of the compounds that we 
identified in our screens inhibited activation through the cytoplasmic 
tail chimera (Figure 1D). We termed these novel PAR1 inhibitors 
parmodulins. 
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Figure 1: Identification of 2 classes of PAR1 antagonists. (A) Structure of 
parmodulins. (B) Structure of orthosteric inhibitors. The effect of vehicle (N/A), 10 μM 
parmodulin 1 (PM1), 3 μM parmodulin 2 (PM2), 10 μM parmodulin 3 (PM3), 10 μM 
parmodulin 4 (PM4), 0.3 μM vorapaxar (V), 0.3 μM atopaxar (A), 3 μM SCH79797 (S), 
or 3 μM BMS-200261 (B) on SFLLRN-induced [Ca2+]i was evaluated in COS-7 
transfected with (C) PAR1 or (D) PAR1/PAR4CT, in which the cytoplasmic tail of PAR1 
(white) is replaced with that of PAR4 (gray). Increase in [Ca2+]i flux after stimulation 
with 5 μM SFLLRN was evaluated. Data are presented as means ± standard error of 
the mean (SEM) (n = 6). 
Mechanism of action of parmodulins 
Orthosteric PAR1 inhibitors and parmodulins were subsequently 
tested in platelets. All compounds blocked SFLLRN-induced platelet 
aggregation (Figure 2A-B). Inhibition of platelet aggregation by 
parmodulins was reversed after platelets were washed (Figure 2A), 
whereas washing did not reverse inhibition of platelet aggregation by 
orthosteric inhibitors (Figure 2B). Aggregometry tracings 
demonstrated that parmodulins failed to inhibit platelet shape change 
even at concentrations that totally blocked platelet aggregation, 
whereas orthosteric inhibitors blocked both shape change and 
aggregation (supplemental Figure 2A). To evaluate the activity of PAR1 
antagonists on downstream signaling, we tested their effect on Gαq-
mediated [Ca2+]i flux, which is required for aggregation,28 and on Gα13-
mediated activation of RhoA, which is required for shape change.29 All 
compounds inhibited SFLLRN-stimulated [Ca2+]i flux (Figure 2C), 
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indicating inhibition of Gαq-mediated signaling. However, although 
orthosteric inhibitors completely blocked activation of Gα13-mediated 
activation of RhoA, PAR1-mediated GDP/GTP exchange at RhoA could 
be detected in the presence of parmodulins (Figure 2D). Densitometry 
of multiple samples confirmed this result (supplemental Figure 2B). 
These studies demonstrate that parmodulins inhibit PAR1 activation via 
a mechanism that is distinct from that of orthosteric inhibitors and 
involves selective inhibition of Gα subunits. 
 
Figure 2: Parmodulins inhibit signaling mediated through platelet Gαq, but not 
Gα13. Platelets were incubated in the presence (black line) or absence (dark gray line) 
of (A) 10 μM parmodulin 1 (PM1), 3 μM parmodulin 2 (PM2), 10 μM parmodulin 3 
(PM3), or 10 μM parmodulin 4 (PM4); or (B) 0.3 μM vorapaxar, 0.3 μM atopaxar, 1 μM 
SCH79797, or 3 μM BMS-200261, and subsequently stimulated with 5 μM SFLLRN. 
Reversibility was assessed after washing platelets incubated with PAR1 antagonists 
and exposing them to 5 μM SFLLRN (light gray line). (C) Platelets were incubated with 
parmodulins or orthosteric PAR1 agonists as described in (A) and (B), respectively, 
and evaluated for [Ca2+]i flux after incubation with 5 μM SFLLRN. Data are presented 
as means ± SEM (n = 4). (D) Platelets were incubated with the indicated PAR1 
antagonists at the concentrations described in the previous legends and subsequently 
exposed to vehicle (–) or 10 μM SFLLRN (+). Activation of RhoA after exposure to 
SFLLRN was evaluated. 
The observation that parmodulins act by a common mechanism 
involving the cytosolic face of PAR1 to selectively inhibit downstream 
signaling was unexpected because these compounds were all identified 
in a screen of ligand-induced activation.22,25,26 Equilibrium-binding 
studies were therefore performed using parmodulins 1 and 2 to 
determine whether they affect agonist association with the ligand 
binding site of PAR1. [3H]haTRAP, a high-affinity PAR1 orthosteric 
ligand, was used to monitor binding to PAR1 on platelet membranes.14 
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[3H]haTRAP bound platelet membranes with a Kd of 6.87 nM ± 0.9 and 
a Bmax of 7.73 ± 0.47 pmol/mg. Incubation of platelet membranes with 
parmodulin 1 or parmodulin 2 did not significantly affect binding of 
[3H]haTRAP to platelet membranes (Figure 3A), consistent with 
experiments demonstrating activity at the intracellular face of PAR1. In 
contrast, the orthosteric inhibitor SCH79797 (1 μM) blocked binding of 
[3H]haTRAP (Figure 3A). These studies support the hypothesis that 
parmodulin 1 and parmodulin 2 act outside the ligand-binding site 
without substantially altering the PAR1 ligand–binding site. 
 
Figure 3: Parmodulins bind outside the ligand-binding pocket and act at the 
intracellular face of PAR1. (A) Equilibrium radioligand-binding studies were 
performed as described in “Methods.” The effect of vehicle (closed triangles), 
parmodulin 1 (open diamonds), parmodulin 2 (closed squares), and SCH79797 (open 
circles) on bound (B) and free (F) [3H]TRAP after incubation with platelet membranes 
was evaluated. The effect of vehicle (N/A), 10 μM parmodulin 1 (PM1), 3 μM 
parmodulin 2 (PM2), and 1 μM SCH79797 (S) on agonist-induced [Ca2+]i flux was 
evaluated in COS-7 transfected with (B) wild-type (WT) PAR1, (C) WT PAR4, (D) the 
ΔH8 PAR1 mutant, (E) a chimeric PAR1 in which il2 was replaced with il2 of PAR4, and 
(F) a chimeric PAR1 in which il3 was replaced with il3 of PAR4. [Ca2+]i flux was 
evaluated after stimulation with either 5 μM SFLLRN (B,D-F) or 300 μM AYPGKF (C). 
Data are presented as means ± SEM (n = 3-6). Results were analyzed using a 
Bonferroni multiple comparison test as described in supplemental Table 1 (*P < .05). 
To better define the molecular basis of the effect of parmodulins 
at PAR1, their activity was evaluated in studies using mutant PAR1 and 
PAR1/PAR4 chimeric receptors (see supplemental Figure 1 for receptor 
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expression levels). Parmodulin 1, parmodulin 2, and the orthosteric 
inhibitor SCH79797 blocked [Ca2+]i flux stimulated by SFLLRN when 
tested in COS-7 cells overexpressing PAR1 (Figure 3B), but they failed 
to block activation induced by the PAR4-specific agonist AYPGKF in 
COS-7 cells overexpressing PAR4 (Figure 3C and supplemental Table 
1). To assess the role of helix 8 in parmodulin activity, a PAR1 mutant 
in which residues 376 to 386 had been replaced with 3 alanine 
residues (ΔH8 PAR1) was tested.30 Neither parmodulin 1 nor 
parmodulin 2 significantly blocked activation of the ΔH8 PAR1 mutant 
(Figure 3D and supplemental Table 1). In contrast, SCH79797 
inhibited this mutant as effectively as it inhibited wild-type PAR1. 
Activation of a chimera in which intracellular loop 2 of PAR1 was 
replaced by that of PAR4 (PAR1/PAR4 il2) was significantly inhibited by 
parmodulins (Figure 3E and supplemental Table 1). Yet parmodulins 
did not inhibit activation of a chimera in which intracellular loop 3 of 
PAR1 was replaced by that of PAR4 (PAR1/PAR4 il3; Figure 3F and 
supplemental Table 1), implicating intracellular loop 3 in parmodulin 
activity. SCH79797 inhibited activation-induced [Ca2+]i flux in both 
intracellular loop chimeras effectively (Figure 3E-F). These studies 
indicate a role for il3 and helix 8 in conferring sensitivity to these two 
structurally unrelated parmodulins. 
Parmodulins demonstrate selective antagonism in 
endothelial cells 
Activation of PAR1 by thrombin or SFLLRN stimulates a dramatic 
phenotypic change in endothelial cells characterized by exocytosis, loss 
of barrier function, and contraction. We compared the ability of 
parmodulins and orthosteric inhibitors to block PAR1-mediated 
proinflammatory signaling in endothelial cells. All PAR1 antagonists 
blocked PAR1-stimulated Gαq-mediated activation as detected by 
monitoring [Ca2+]i (Figure 4A-B). The potency of inhibition of 
endothelial-cell PAR1 was roughly equivalent to the inhibition of 
platelet PAR1.12-16,22,25-27 Parmodulin 2 was the most potent and 
selective parmodulin and demonstrated relatively little off-target 
activity when tested in GPCR profiling studies (supplemental Figure 
3A). In addition, selectivity was evaluated in endothelial cells, in which 
parmodulin 2 inhibited PAR1-mediated secretion of VWF, but not 
secretion induced by histamine, DDAVP, epinephrine, or PMA 
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(supplemental Figure 3B). Inhibition of PAR1 signaling in endothelial 
cells was reversible (supplemental Figure 4A) and selective for Gαq 
over Gα12/13 (Figure 4A and supplemental Figure 4B). Parmodulin 2 and 
vorapaxar inhibited PAR1-mediated endothelial cell Weibel-Palade body 
exocytosis, as indicated by secretion of VWF (Figure 4C and 
supplemental Figure 4C). Parmodulin 2 and vorapaxar also inhibited 
thrombin-induced endothelial cell contraction (Figure 4D). Further, 
parmodulin 2 and vorapaxar inhibited PAR1-mediated loss of barrier 
function, as evidenced by a transendothelial cell resistance assay 
(Figure 4E-F). 
 
Figure 4: Parmodulin 2 and vorapaxar inhibit proinflammatory signaling in 
endothelial cells. HUVECs were incubated with the indicated concentrations of (A) 
parmodulins or (B) orthosteric inhibitors for 30 minutes before exposure to SFLLRN. 
Increase in [Ca2+]i flux after stimulation with 5 μM SFLLRN was evaluated and 
compared with vehicle controls that were not exposed to PAR1 antagonists. Data are 
presented as means ± SEM (n = 3-6). (C) HUVECs were incubated with either 3 μM 
parmodulin 2 (PM2) or 0.3 μM vorapaxar before exposure to vehicle (black) or SFLLRN 
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(red). Release of von Willebrand factor (VWF) into supernatants was quantified by 
ELISA. Data are presented as means ± SEM (n = 4). ***P < .001. (D) 
Immunofluorescence microscopy of HUVECs incubated with vehicle, parmodulin 2, or 
vorapaxar, exposed to buffer or 1 U/ml thrombin, and subsequently stained with PE-
phalloidin and DAPI. (E) Representative tracings of real-time monitoring of 
transendothelial electric resistance (TER) of HMVECs incubated with vehicle, 10 μM 
parmodulin 2, or 0.3 μM vorapaxar and subsequently exposed to SFLLRN (arrow). (F) 
Quantification of inhibition of SFLLRN- and thrombin-induced barrier dysfunction in 
HMVECs by parmodulin 2 and vorapaxar. *P < .05, **P < .01, ***P < .001. 
In contrast to the proinflammatory signaling elicited by 
thrombin, cleavage of endothelial cell PAR1 by APC results in a 
cytoprotective program that prevents barrier dysfunction, exocytosis, 
and apoptosis induced by chemokines such as tumor necrosis factor-α 
(TNF-α) or toxins.5-8,31,32 A potential liability of inhibition at PAR1 is 
interference with cytoprotective endothelial signaling stimulated by 
APC. We compared the ability of orthosteric inhibitors and parmodulins 
to block APC-mediated cytoprotection from TNF-α–induced apoptosis. 
Application of APC before TNF-α exposure protected endothelial cells 
from TNF-α–induced apoptosis (Figure 5A). Knockdown of PAR1 using 
PAR1-specific siRNA reversed the antiapoptotic effect of APC, 
confirming that APC acts through PAR1 (Figure 5A). In subsequent 
studies, endothelial cells were exposed to either PM2 or vorapaxar 
before incubation with APC. Cells were then exposed to TNF-α to 
determine whether APC-mediated protection from apoptosis was 
inhibited. Endothelial cells exposed to vorapaxar phenocopied cells in 
which PAR1 had been knocked down, demonstrating that vorapaxar 
blocks APC-mediated protection from apoptosis (Figure 5B). In 
contrast, parmodulin 2 did not block APC-mediated protection from 
apoptosis (Figure 5B). These results demonstrate that parmodulins 
interfere with thrombin-induced endothelial stimulation without 
blocking APC-induced protection from apoptosis. 
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Figure 5: Vorapaxar, but not parmodulin 2, blocks APC-mediated 
cytoprotection in endothelial cells. (A) Mock-transfected and PAR1 siRNA–
transfected (siPAR1) HUVECs were incubated in the presence of buffer (N/A) or APC 
before exposure to vehicle or TNF-α. Incubation with APC inhibits apoptosis induced by 
TNF-α in mock-transfected HUVECs, but not cells in which PAR1 has been knocked 
down. (B) Endothelial cells were incubated in the presence of vehicle (white), 10 μM 
parmodulin 2 (black), or 0.3 μM vorapaxar (gray) for 30 minutes. Samples were then 
exposed to either buffer or APC for 4 hours. Indicated samples were subsequently 
stimulated with TNF-α and analyzed for apoptosis. Data are presented as means ± 
SEM (n = 5). *P < .05, **P < .01. 
Vorapaxar, but not parmodulin 2, induces endothelial 
cell injury 
While evaluating the effect of vorapaxar on endothelial cell 
phenotypes, we observed that longer incubations with vorapaxar 
induced apoptosis (Figure 6A). A 24-hour exposure to vorapaxar 
induced endothelial cell apoptosis in a dose-dependent manner, with 
significant apoptosis occurring at 300 nM (Figure 6B). Increasing the 
length of exposure increased the sensitivity of endothelial cells to 
vorapaxar such that after 48 hours, significant apoptosis was observed 
at 100 nM (Figure 6B). These concentrations are in the range of 
predicted plasma concentrations achieved with the dosing regimens 
used in the TRACER and TRA-2P studies.17,18 Similarly, atopaxar, 
SCH79797, and BMS-200261 all induced apoptosis in endothelial cells 
(supplemental Figure 5). In contrast, no significant increase in 
apoptosis was observed when endothelial cells were incubated with 
parmodulin 2 at concentrations as high as 30 μM (Figure 6A-B) or 
hirudin (not shown). 
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Figure 6: Vorapaxar, but not parmodulin 2, induces endothelial dysfunction 
upon prolonged exposures. (A) HUVECs were exposed to vehicle alone, 10 μM 
parmodulin 2, or 0.3 μM vorapaxar, as indicated, for 48 hours and subsequently 
stained for apoptosis using YO-PRO-1. (B) HUVECs were incubated with the indicated 
concentrations of either vorapaxar (blue) or parmodulin 2 (red) for either 24 hours 
(solid lines) or 48 hours (dashed lines) and assayed for apoptosis. Data are presented 
as means ± SEM (n = 5). (C) Mock-transfected (mock) and PAR1 siRNA–transfected 
(siPAR1) HUVECs were incubated with either vehicle (black) or 0.3 μM vorapaxar 
(blue) for either 24 or 48 hours. Samples were subsequently assayed for apoptosis. In 
each condition, addition of vorapaxar led to a significant increase in apoptosis 
compared with the unexposed sample (P < .001). Knockdown of PAR1 also increased 
apoptosis. ***P < .001. Data are presented as means ± SEM (n = 5). (D) HMVEC 
barrier function was continuously monitored by transendothelial resistance for 24 
hours after exposure to either 10 μM parmodulin 2 (red) or 0.3 μM vorapaxar (blue). 
***P < .001. 
PAR1 antagonist–induced endothelial apoptosis could be caused 
by a biased agonist effect of inhibitors that act at the ligand-binding 
site. Alternatively, constitutive PAR1 activity could be important for 
endothelial cell survival33,34 and PAR1 blockade could result in 
apoptosis. To distinguish between these 2 possibilities, we evaluated 
the effect of long-term vorapaxar exposure on endothelial cell 
apoptosis after knockdown of PAR1. Transfection with PAR1-targeted 
siRNA resulted in >90% knockdown. Incubation of PAR1 siRNA-
transfected cells with 300 nM vorapaxar stimulated increased 
apoptosis compared with incubation with mock-transfected cells at 
both 24 and 48 hours (Figure 6C). In addition, there was significant 
apoptosis in the absence of vorapaxar at 48 hours. Endothelial cell 
apoptosis after PAR1 knockdown and 48-hour exposure to 1 or 3 μM 
vorapaxar could not be quantified because the cells no longer adhered 
to the plate. A 24-hour incubation with vorapaxar also induced 
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significant endothelial barrier dysfunction compared with parmodulin 2 
(Figure 6D). These observations indicate that long-term exposure to 
vorapaxar, but not parmodulin 2, elicits endothelial cell injury. 
Effect of parmodulin 2 on thrombosis and hemostasis 
PAR inhibition impairs thrombus formation in both animal 
models and clinical studies but is associated with bleeding.17-20 We 
therefore studied parmodulin 2 in assays of both thrombosis and 
hemostasis. When tested in a murine model in which thrombosis is 
elicited by laser-induced injury of cremaster arterioles, parmodulin 2 
(5 mg/kg) reduced platelet accumulation during thrombus formation 
by 73% (Figure 7A-B). Because PAR4 is the dominant PAR on mouse 
platelets, we determined whether parmodulin 2 inhibited aggregation 
induced through murine PAR4. Previous studies demonstrated that 
parmodulin 1 interacts with a limited number of GPCRs, including 
murine PAR4, that have common features at helix 8.30 These features 
include a predicted ionic interaction between position 1 of helix 8 and 
the il1 loop, H-bond formation between position 3 of helix 8 and 
transmembrane domain 7, a hydrophobic interaction between the 
tyrosine of the NPxxY motif and an aromatic amino acid at position 2 
of helix 8, and a palmitoylation site(s) at the C terminus of helix 8.22 
Like parmodulin 1, parmodulin 2 blocked AYPGKF-induced aggregation 
of mouse platelets (Figure 7C), but not AYPGKF-induced aggregation 
of human platelets (supplemental Figure 6). Thus, parmodulin 2 
inhibits activation through murine PAR4, but not human PAR4. For 
hemostasis assays, parmodulin 2 (5 mg/kg) was infused into mice 
before tail-tip amputation. Parmodulin 2 failed to affect bleeding times 
(Figure 7D) or hemoglobin loss (Figure 7E) after transection of the tail 
tip. These results show that parmodulin 2 inhibits platelet 
accumulation during thrombus formation but does not affect 
hemostasis in this model. 
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Figure 7: Parmodulin 2 inhibits thrombus formation without prolonging 
bleeding times. (A) Platelet-specific anti-GPIbβ antibody conjugated to Dylight 649 
(0.1 µg/g body weight) was infused into mice. Thrombi were induced by laser injury of 
cremaster arterioles before (n = 62 thrombi in 7 mice) and after (n = 54 thrombi in 7 
mice) infusion of parmodulin 2 (5 mg/kg body weight). Thrombus formation was 
visualized by videomicroscopy for 180 seconds after injury. Representative binarized 
images of platelets at the injury site before (Control) and after parmodulin 2 infusion 
(PM2) are shown. White arrowheads indicate the location of the vessel. (B) Median 
integrated platelet-fluorescence intensity at the injury site in mice before (Control) 
and after parmodulin 2 infusion (PM2) is plotted over time. (C) Mouse platelet 
aggregation in response to 65 μM AYPGKF was evaluated after incubation with the 
indicated concentrations of parmodulin 2. (D) Time to cessation of bleeding and (E) 
total hemoglobin loss was measured after tail-tip amputation. 
Discussion 
These studies distinguish between 2 distinct classes of small 
molecules capable of modulating PAR1 activity. Orthosteric PAR1 
inhibitors that induce potent and effective blockade of the binding site 
of the tethered ligand have been developed,17,18,35,36 and one of these, 
vorapaxar, has recently been approved for secondary prevention of 
cardiovascular events. As a class, these inhibitors bind tightly to PAR1. 
They are inhibitory in the nanomolar range because they must 
compete with a tethered ligand that has an effective concentration 
estimated to be 400 μM.1 As a result of the tight binding of orthosteric 
antagonists, their inhibition is not readily reversible. Blockade at the 
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ligand binding site results in inhibition of all ligand-induced 
downstream signaling. We now describe a second class of small-
molecule PAR1 inhibitors, the parmodulins, which distinguish 
themselves on the basis of their site of action at the cytosolic face of 
PAR1 and selectivity at the level of G-protein coupling. As a class, 
parmodulins are less potent than orthosteric PAR1 antagonists and 
demonstrate reversible antagonism. Studies in platelets show that 
they inhibit PAR1-dependent Gαq-mediated elevation of [Ca2+]i flux, 
but not Gα12/13-mediated signal transduction. The selectivity of 
parmodulins remains to be fully defined. Our initial profiling and 
functional assays (supplemental Figure 3), however, indicate that 
parmodulin 2 is the most selective and parmodulins 3 and 4 are the 
least selective.25-27 Nonetheless, the fact that parmodulins all 
demonstrate selectivity at the level of PAR1-mediated signaling 
transduction defines them as a new class of small-molecule PAR1 
modulators that act at an intracellular site on PAR1. 
The functional significance of these distinct modes of PAR1 
inhibition is best exemplified in the effects of parmodulin 2 and 
vorapaxar on endothelial cell function (supplemental Figure 7). Both 
PAR1 antagonists block proinflammatory signaling in endothelial cells 
(Figure 4). However, although parmodulin 2 spares APC-mediated 
cytoprotection, vorapaxar blocks this pathway (Figure 5). In addition, 
incubation with vorapaxar induces endothelial injury upon prolonged 
exposure (Figure 6). Importantly, endothelial injury was observed at 
concentrations approximating vorapaxar plasma levels achieved with 
dosing protocols used in TRACER or TRA-2P, as indicated by earlier 
pharmacokinetic studies.37,38 The fact that PAR1 knockdown increased 
susceptibility of endothelial cells to vorapaxar-induced apoptosis 
suggests that constitutive PAR1 signaling is required for endothelial 
cell viability. Impaired endothelial growth and vascular formation were 
observed during development in PAR1−/− mice,33,34 indicating that 
PAR1 functions in endothelial cell viability in vivo. PAR1 deficiency 
resulted in 50% embryonic lethality associated with diffuse 
hemorrhage. Bleeding was reversed with endothelial cell–specific 
expression of PAR1, raising the possibility that endothelial PAR1 
functions in hemostasis.34 The dominant complication of vorapaxar in 
TRACER and TRA-2P was major bleeding.19,20 Whether exposure to 
vorapaxar or other orthosteric PAR1 antagonists induces endothelial 
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cell injury that constitutes an additional risk factor for bleeding beyond 
the antiplatelet effect requires further investigation. 
Parmodulins validate the strategy of using small molecules to 
target the cytosolic face of GPCRs to selectively block one downstream 
signaling pathway while preserving another. GPCRs demonstrate 
modularity between the extracellular (ligand-binding) and intracellular 
(G-protein–binding) regions.39 Association of parmodulin 1 or 2 with 
PAR1 does not dramatically affect the ligand-binding site, as indicated 
by their ability to bind PAR1 without significantly modifying the binding 
of [3H]ha-TRAP. Consistent with this observation, studies using 
chimeric PARs indicate that interactions at the intracellular face of 
PAR1 are required for parmodulin activity. Lipidated peptides modeled 
after the intracellular loops of PAR1 have been developed and have 
either antagonist or agonist activity at PAR1.40,41 Parmodulin activity, 
however, is likely more analogous to small-molecule inhibitors directed 
against the cytoplasmic face of CCR4 and CXCR2. These chemokine 
inhibitors are thought to act at a binding site within or adjacent to the 
G-protein–binding pocket.42-44 Mutational studies suggest that different 
classes of G-proteins associate with different regions on the 
cytoplasmic face of PAR1.45 Parmodulins could bind at or near the G-
protein–binding pocket and selectively compete with Gαq, but not 
Gα12/13. The ability of antagonists that target an intracellular site to 
selectively impair downstream G-protein signaling has not previously 
been studied. Our data show that by targeting the cytosolic face of 
PAR1, parmodulins inhibit PAR1-induced proinflammatory signaling in 
endothelial cells without blocking APC-mediated cytoprotection 
signaling through PAR1. In vivo, these compounds block arteriolar 
thrombosis without increasing bleeding times after tail clip. 
Parmodulins represent a prototype for the identification and 
characterization of compounds that target the cytosolic face of GPCRs 
to selectively inhibit coupling to some Gα subunits, but not others. 
Small molecules targeting the G-protein–binding site will be useful in 
dissecting the molecular determinants of GPCR–G-protein coupling and 
developing new approaches to pharmacologically manipulate that 
coupling. Ultimately, such compounds could be used to inhibit 
pathways that mediate pathologic signaling while preserving or even 
stimulating protective signaling pathways. 
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